This clinical study showed that intratumoral injection of MV after systemic treatment by IFN-α (to avoid MV infection in IFN-α-sensitive healthy cells) induced local infection and a characteristic cytopathogenic effect of MV on tumor cells which was not abrogated by the presence of preexisting MV antibodies. This evidence concerns the gene IFNA1 and neoplasm.